NEW YORK (GenomeWeb News) – Danish proteomics firm Proxeon has raised DKK14 million ($2.4 million) in a round of private financing from venture capital investors.

The firm did not say in its statement who the venture capital investors are for this round, but according to the firm's website investment firms Vecata and Inventure Capital are among its investors.

Proxeon said that the investment is expected to be sufficient to help the firm reach positive cash flow. It also noted that it expects to record full-year 2008 revenue growth of more than 60 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.